Editorial
What's in a name? The overlap between tumour typing and grading highlighting deficiencies in nomenclature
W Glenn McCluggage,
Corresponding Author
W Glenn McCluggage
Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
Address for correspondence: W Glenn McCluggage, Department of Pathology, Belfast Health and Social Care Trust, Grosvenor Road, Belfast BT12 6BA, UK. e-mail: [email protected]Search for more papers by this authorW Glenn McCluggage,
Corresponding Author
W Glenn McCluggage
Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
Address for correspondence: W Glenn McCluggage, Department of Pathology, Belfast Health and Social Care Trust, Grosvenor Road, Belfast BT12 6BA, UK. e-mail: [email protected]Search for more papers by this authorNo abstract is available for this article.
Conflicts of interest
The author has no conflicts of interest.
References
- 1Singh N, Gilks CB, Wilkinson N, McCluggage WG. The secondary Mullerian system, field effect, BRCA, and tubal fimbria: Our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology 2015; 47; 423–431.
- 2Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 2014; 65; 149–114.
- 3Singh N, Gilks CB, Hirshowitz L, Wilkinson N, McCluggage WG. Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come. Int. J. Gynecol. Pathol. 2016; 35; 230–237.
- 4Singh N, Gilks CB, Hirschowitz L et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol. Oncol. 2016; 141; 195–198.
- 5de Kock L, Terzic T, McCluggage WG et al. DICER1 mutations are consistently present in moderately and poorly differentiated Sertoli-Leydig cell tumors. Am. J. Surg. Pathol. 2017; 41; 1178–1187.
- 6McCluggage WG, Rivera B, Chong AS et al. Well-differentiated Sertoli-Leydig cell tumors (SLCTs) are not associated with DICER1 pathogenic variants and represent a different tumor type to moderately and poorly differentiated SLCTs. Am. J. Surg. Pathol. 2022. https://doi.org/10.1097/PAS.0000000000002010 Online ahead of print, Publish Ahead of Print.
- 7Heravi-Moussavi A, Anglesio MS, Cheng SW et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med. 2012; 366; 234–242.
- 8Foulkes WD, Gore M, McCluggage WG. Rare non-epithelial ovarian neoplasms: pathology, genetics and treatment. Gynecol. Oncol. 2016; 142; 190–198.
- 9Koontz JI, Soreng AL, Nucci M et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc. Natl. Acad. Sci. U.S.A. 2001; 98; 6348–6353.
- 10Lee CH, Mariño-Enriquez A, Ou W et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: A histologically high-grade and clinically aggressive tumor. Am. J. Surg. Pathol. 2012; 36; 641–653.
- 11Hoang LN, Aneja A, Conlon N et al. Novel high-grade endometrial stromal sarcoma: a morphologic mimicker of myxoid leiomyosarcoma. Am. J. Surg. Pathol. 2017; 41; 12–24.
- 12Marinõ-Enriquez A, Lauria A, Przybyl J et al. BCOR internal tandem duplication in high-grade uterine sarcomas. Am. J. Surg. Pathol. 2018; 42; 335–341.
- 13Zou Y, Turashvili G, Soslow RA et al. High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Mod. Pathol. 2020; 33; 1861–1870.
Citing Literature
